Sygnature Discovery

Drug discovery services
Date Invested
September 2017

At a glance

PhD-qualified scientists
test tubes used each year
new scientists hired per year

Sygnature is a leading provider of outsourced drug discovery services to UK and overseas biotech and pharma companies. The company employs over 425 staff, the majority of whom hold PhDs.

Sygnature’s people work in partnership with its clients to support them in identifying and developing new molecules in the early stages of the drug development process.

Our partnership

We’re working in partnership with founding CEO, Simon Hirst, and the team to accelerate growth by expanding the business’s international reach and broadening the range of services it provides to its clients. Together we are assessing a number of potential acquisition opportunities, with the first having been completed in the first year of our investment.

"We’re excited to be working with Phoenix – our partnership will give us the investment we need to further expand our business and provide a broader range of services for our customers.”

Simon Hirst, CEO of Sygnature